FUNMAN About - Profile | InvestorsHub

DON'T MISS YOUR FREE DAILY BRIEFING!

Subscribe to our daily news briefing, partner offers and other newsletters catered to investors like you!

Stock Options

NEW to INVESTORSHUB

FUNMAN

Followers	109
Posts	26,009
Boards Moderated	0
Alias Born	08/03/2010

FUNMAN

Message

FUNMAN

Message

IHub Info
Membership Type:
Followed By:	109
Posts:	26,009
Boards Moderated:	0
Alias Born:	08/03/2010 08:59:36 AM

Personal Info

Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Xcel Brands and G-III Apparel Group, Ltd. Announce Halston Master Licensing Partnership Under New 25-Year Agreement
Crown Electrokinetics Completes Restructuring of Balance Sheet
SEABOURN UNVEILS POWERHOUSE LINE-UP OF SPEAKERS FOR SEABOURN CONVERSATIONS ONBOARD ENRICHMENT PROGRAM
Trending: SEC Sues Coinbase Global
a.k.a. Brands Holding Corp. Announces Share Repurchase Program
Novo Integrated Sciences Receives $40,000,000 Commitment to Develop Eldercare Facilities in Canada
Ciena Reports Fiscal Second Quarter 2023 Financial Results
Palantir Launches Foundry for Manufacturing on AWS to the Broader Market
THOR Industries Announces Third Quarter Fiscal 2023 Results
Wells Fargo to Present at the Morgan Stanley US Financials, Payments & CRE Conference
AgBiome Leverages Ginkgo Strain Optimization Services to Optimize Agricultural Biological Pipeline
Hoth Therapeutics Announces Positive Preclinical Results of HT-ALZ treatment for Alzheimer's Disease
Vistagen Announces Stockholder-Approved Reverse Stock Split
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Splash Beverage Group Reports 2023 First Quarter Financial Results
Intel to Host Internal Foundry Model Investor Webinar
Ford to Recall Over 125,000 Escape, Lincoln Corsair and Maverick Vehicles Over Fire Risk
Bausch Health Shares Drop After Norwich Sues FDA for Final OK for Rival Drug
Xunlei Announces $20 million Share Repurchase Program